analiza aiqbench

InSilico Medicine has put forward ISM9546, a VAV1 degrader that its AI platform helped design, as a candidate for autoimmune disease. A candidate nomination is an early step, so it says little yet about clinical efficacy or safety. For AI readers, the useful question is whether AI-driven discovery shortens or improves the path to viable drugs, which will only be clear once preclinical and clinical data are published.